Application of RNA Transcribed from Viral IRES Control: Utilization of Vaccine Development for MERS-CoV

Identification: Nam, Jae-Hwan


Description

 

Application of RNA Transcribed from Viral IRES Control: Utilization of Vaccine Development for MERS-CoV
 
Hye Won Kwak1, Ryoon Ho Kim1, Hae-Rim Park1, Hyo-Jung Park1, Hae Ri Ko1, Man Ki Song2, Jae-Ouk Kim2, Seung Rok Ryu3, Kyung Won Kang3, Sang-Myeong Lee3, Jae-Hwan Nam1*
1Department of Biotechnology, The Catholic University of Korea; 2International Vaccine Institute; 3Division of Biotechnology, Chonbuk National University
      
In 2015, a large outbreak of the Middle East respiratory syndrome coronavirus (MERS-CoV) occurred in Korea. Since then, a clinically available vaccine has not yet been made available. In this study, we developed a novel RNA adjuvant, i.e., RNA transcribed from plasmid (pCrPV-MERS) including MERS spike (S) gene under internal ribosome entry site (IRES) control of cricket paralysis virus (CrPV) for combinational immunization with MERS S protein. RNA transcribed from pCrPV-MERS was used to treat mouse bone marrow-derived conventional dendritic cells and human peripheral blood mononuclear cells. This showed that the changes in transcriptome and cytokines by RNA treatment were similar to those by poly I:C treatment as positive control, which means that it is possible to use RNA-containing CrPV-IRES as adjuvant. To confirm this in vivo, MERS S protein is intramuscularly immunized to mouse with/without alum and RNA transcribed from pCrPV-MERS as adjuvant. The RNA adjuvant immunized group showed higher neutralizing antibody and IgG2a (indicated Th1-oriented response) levels against MERS S compared with the mouse group immunized with S protein without RNA from pCrPV-MERS. Furthermore, the population of T cells secreting IFN- (indicated cytotoxic T lymphocyte, CTL, response) from splenocytes of RNA adjuvant-immunized group is higher than that of MERS S protein immunized group after priming with S protein and peptide. However, both groups showed a protection effect against the MERS-CoV challenge. All data indicated that RNA transcribed from IRES of CrPV as adjuvant can trigger Th1 and CTL immune responses, which means that a RNA adjuvant including a gene of interest (GOI) under CrPV-IRES can induce a specific cellular immune response against GOI. Furthermore, RNA adjuvant-immunized group induced high neutralizing antibody. Therefore, it is a good vaccine strategy because the immunization with alum-formulated protein vaccine and RNA vaccine as adjuvant together can induce both humoral immune response by protein vaccine and cellular immune response by RNA vaccine, which are mutually complementary.
 

 

Credits

Credits: None available.

You must be logged in and own this product in order to post comments.